Skip to main content
LPCN
NASDAQ Life Sciences

Shareholders Approve Significant Expansion of Equity Incentive Plan, Authorizing 1 Million Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.21
Mkt Cap
$18.22M
52W Low
$1.81
52W High
$12.37
52W Position info
22% above low
Off High info
82% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LPCN sits 22% above its 52-week low of $1.81 on light trading volume (0.2× avg).

Summary

Lipocine Inc. shareholders approved a significant expansion of the company's equity incentive plan, authorizing up to 1,000,000 shares for future grants, which could lead to substantial dilution.


Key Events · Corporate Governance and Compliance · LPCN

  • Equity Incentive Plan Expanded

    Shareholders approved an amendment to the 2014 Stock and Incentive Plan, increasing the total authorized shares for issuance to 1,000,000.

  • Increased Individual Award Limits

    The maximum individual award limit under the plan was raised from 25,000 to 100,000 shares.

  • Potential Dilution

    The newly authorized shares represent a significant potential dilution for current shareholders, given the company's market capitalization.

  • Routine Shareholder Votes

    Shareholders also elected directors, ratified the auditor, and approved executive compensation in non-binding votes.


Analysis · LPCN · Life Sciences

Lipocine Inc. shareholders approved an amendment to the 2014 Stock and Incentive Plan, increasing the total authorized shares for issuance to 1,000,000. This represents a substantial potential dilution for existing shareholders, as these shares can be granted to employees and directors over time. This approval finalizes a proposal previously disclosed in April, making the potential dilution concrete.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LPCN was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2M. The 52-week trading range was $1.81 to $12.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LPCN - Latest Insights

LPCN
Nov 13, 2026, 3:23 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.45 info
Change: -$0.2399 (-14%) info
Market Cap: $16.61M info
LPCN
Nov 05, 2026, 9:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.45 info
Change: -$0.0199 (-1%) info
Market Cap: $16.61M info
LPCN
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.45 info
Change: +$0.0001 (+0.01%) info
Market Cap: $16.61M info
LPCN
Oct 07, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.45 info
Change: -$0.7099 (-33%) info
Market Cap: $16.61M info
LPCN
Sep 14, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.45 info
Change: -$0.8199 (-36%) info
Market Cap: $16.61M info